Madrigal Pharmaceuticals, Inc. (MDGL) is listed on NASDAQ in Pharmaceutical Stocks. It is $534.20, -1.75%, with a $12.3B market cap. RSI is 52.0, neutral. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 52.0 Neutral
Market Cap $12.3B
Volume 257.1K
Fundamentals — 10-Q Q2 2026
Revenue $675.6M
Net Income $-152.3M
EPS $-5.24
Operating Margin -22.1%
Net Margin -22.5%
Debt / Equity 0.7x
P/E Ratio -101.9x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Kelley Shannon T | General Counsel | Sell | 664 | $514.97 | $341,940 | 2026 Aug 17 |
| Sibold William John | President and CEO | Sell | 2,500 | $547.30 | $1.4M | 2026 Jul 20 |
| Soergel David | Chief Medical Officer | Sell | 1,042 | $495.74 | $516,561 | 2026 Jun 1 |
| Levy Richard S | Director | Sell | 5,682 | $515.44 | $2.9M | 2026 May 22 |
| Soergel David | Chief Medical Officer | Sell | 844 | $515.90 | $435,420 | 2026 May 18 |
| Dier Mardi | EVP and CFO | Sell | 1,982 | $430.87 | $853,993 | 2026 Mar 6 |
| Sibold William John | President and CEO | Sell | 1,663 | $431.94 | $718,316 | 2026 Mar 6 |
| Kelley Shannon T | General Counsel | Sell | 360 | $431.94 | $155,498 | 2026 Mar 6 |
| Huntsman Carole | Chief Commercial Officer | Sell | 419 | $431.94 | $180,983 | 2026 Mar 6 |
| Taub Rebecca | Director | Sell | 491 | $431.94 | $212,083 | 2026 Mar 6 |
| Dier Mardi | EVP and CFO | Sell | 1,183 | $427.21 | $505,389 | 2026 Mar 2 |
| Taub Rebecca | Director | Sell | 18,650 | $552.15 | $10.3M | 2025 Dec 10 |
| Friedman Paul A | Director | Sell | 24,800 | $552.18 | $13.7M | 2025 Dec 10 |
| Sibold William John | President and CEO | Sell | 2,400 | $575.34 | $1.4M | 2025 Dec 4 |
| Dier Mardi | EVP and CFO | Sell | 4,173 | $578.34 | $2.4M | 2025 Dec 2 |
| Huntsman Carole | Chief Commercial Officer | Sell | 1,958 | $553.11 | $1.1M | 2025 Nov 21 |
| Levy Richard S | Director | Sell | 8,500 | $520.96 | $4.4M | 2025 Nov 13 |
| Bate Kenneth | Director | Sell | 16,575 | $484.31 | $8.0M | 2025 Nov 5 |
| Sibold William John | President and CEO | Sell | 7,279 | $445.63 | $3.2M | 2025 Sep 9 |
| Sibold William John | President and CEO | Sell | 7,616 | $400.17 | $3.0M | 2025 Aug 21 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $199.01 | 34.8 | $10.4B |
| | $113.32 | 33.7 | -- |
| | $118.52 | 47.9 | $25.9B |
| | $16.34 | 45.3 | $18.8B |
Take MDGL further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put MDGL in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Madrigal Pharmaceuticals, Inc. next reports.
Set alerts on MDGL
Get notified when Madrigal Pharmaceuticals, Inc. hits your price targets or technical conditions are met.
Get Started Free